Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer

NCT ID: NCT00221169

Last Updated: 2009-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-10-31
• Study Completion Date: 2009-01-31

Brief Summary

Radiation therapy is an important part of the treatment for lung cancer when treatment intent is for cure. Radiation is a local modality of treatment, that is, it only treats the area that the radiation can target. Therefore it is critical to be able to visualize all the areas of tumor involvement. With current imaging tests such as computed tomography scans (CT), the scans may not be sensitive enough to detect all areas of cancer involvement but with newer imaging tests, such as positron emission tomography (PET), the investigators may be able to better target all the tumor that the CT scan may miss. There are two clinical trials being conducted by the Ontario Clinical Oncology Group (OCOG)looking at PET in lung cancer. This proposal is a companion study to the OCOG PET lung trials. In brief, this study will evaluate the ability of CT alone versus combined PET CT imaging to determine the size of the tumor (or gross tumor volume) along with the tiny extensions of cancer cells (or microscopic extension). The gross tumor volume and its extension as determined by CT or PET CT will then be compared to measurements made on the surgically removed tumor. Treatment with radiation therapy must include all the gross tumor and its extension in order to be successful for cure. If the radiation treatment does not treat all the identified tumor then the chance for cure is lost. There have only been two previous reports of the ability of CT to determine the gross tumor volume and its extension. There are no similar reports using PET CT. This study will be the first of its kind to evaluate how accurate PET CT can be in detecting the gross tumor and its microscopic extension using the surgically removed tumor measurements as the gold standard. If PET CT is able to more accurately determine the tumor volume including its microscopic extension, then this will help oncologists to better treat lung cancer using more accurate radiation treatment volumes.

Detailed Description

Radiation therapy is an important component in the curative treatment of non-small cell lung cancer. Targeting of the gross tumor has been facilitated by the use of CT simulation allowing for more accurate delineation of the tumor. In addition multi-modality imaging combining functional and anatomical information have allowed for further refinement in the treatment planning process with significant impact on the planning target volume due to the addition of PET imaging information. PET using 18 F-fluorodeoxyglucose (FDG) allows for more precise detection of tumor since it is a functional image based on glucose metabolism rather than structural abnormalities. Biochemical changes often precede any gross anatomical abnormalities, therefore making PET a very powerful imaging modality. FDG PET has been shown to be more sensitive and specific than CT in the staging of NSCLC.Radical radiation therapy is indicated for early stage NSCLC when the patient is medically inoperable primarily due to co-morbidities. In contrast for locally advanced NSCLC, radical radiation is used as part of induction therapy or in the definitive treatment of NSCLC. In order to avoid a geographical miss with precision radiation therapy, the gross tumor volume (GTV) is outlined and a margin around the GTV is added to incorporate microscopic extension of disease, also known as the clinical target volume (CTV). Standard margins of 1.0 to 1.5 cm are used to encompass the gross tumor, microscopic extent and treatment setup uncertainties.There is surprisingly very little data on what constitutes an adequate margin to encompass the microscopic extent around the gross lung tumor. Studies involving conformal radiation therapy and dose escalation in NSCLC have primarily used an empirical margin to define the CTV. A literature review revealed only two studies evaluating the ability of CT to define the gross tumor and its microscopic extension correlated with histopathological measurements [P Giraud et al 2000, R Chan et al 2001]. The two studies have produced conflicting results with recommended margins being from zero mm to 6-8 mm around the GTV. There have been no studies evaluating the ability of PET to define the size of the gross tumor and its microscopic extension.This is a companion study to the two OCOG PET trials in NSCLC. It will evaluate the ability of CT alone versus PET CT to define the gross tumor and its microscopic extension. The methodology will be based on contouring the GTV with imaging modalities of CT and PET CT and correlating the findings with histopathology.This proposed study will add new information on the ability of combined PET CT to determine the microscopic extension of tumor in NSCLC. While no imaging modality can detect microscopic extension, the newer technology of PET CT may give better resolution over CT alone in the detection of tumor. The strength of this proposal is the required correlation with pathological findings. If PET CT is able to accurately determine the extent of disease, this will have major implications on treatment volumes and subsequent targeting for radiation therapy using 3D conformal radiation therapy.

Conditions

Non-Small Cell Lung Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

surgical candidates

surgical candidates who underwent PET CT evaluation

Group Type: OTHER

Surgical resection

Intervention Type: PROCEDURE

pet ct prior to surgery

Interventions

Surgical resection

pet ct prior to surgery

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Surgically resectable non-small cell lung cancer
• Companion clinical trial to OCOG PET Lung trials

Exclusion Criteria

• Unresectable non-small cell lung cancer
• Unable to undergo PET CT evaluation

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ontario Cancer Research Network

NETWORK

Sponsor Role: collaborator

Ontario Clinical Oncology Group (OCOG)

OTHER

Sponsor Role: collaborator

Toronto Sunnybrook Regional Cancer Centre

OTHER

Sponsor Role: lead

Responsible Party

Sunnybrook Regional Cancer Centre

Principal Investigators

Yee C Ung, MD

Role: PRINCIPAL_INVESTIGATOR

Toronto Sunnybrook Regional Cancer Centre

Locations

Toronto Sunnybrook Regional Cancer Centre

Toronto, Ontario, Canada

Toronto Sunnybrook Regional Cancer Centre

Toronto, Ontario, Canada

Countries

Canada

References

Dahele M, Hwang D, Peressotti C, Sun L, Kusano M, Okhai S, Darling G, Yaffe M, Caldwell C, Mah K, Hornby J, Ehrlich L, Raphael S, Tsao M, Behzadi A, Weigensberg C, Ung YC. Developing a methodology for three-dimensional correlation of PET-CT images and whole-mount histopathology in non-small-cell lung cancer. Curr Oncol. 2008 Oct;15(5):62-9. doi: 10.3747/co.v15i5.349.

Reference Type: RESULT

PMID: 19008992 (View on PubMed)

Other Identifiers

OCRN grant

Identifier Type: -

Identifier Source: secondary_id

04-may-00142 OCRN

Identifier Type: -

Identifier Source: org_study_id